Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Venclexta (venetoclax)
Pharma
AstraZeneca trumpets new Calquence combos in CLL
With the AMPLIFY trial win, the combination of Calquence, venetoclax and Gazyva may become the first triplet regimen in CLL.
Angus Liu
Jul 29, 2024 10:25am
An Imbruvica combo regimen could have a new future in MCL
Dec 12, 2023 12:33pm
AbbVie, Roche's Venclexta disappoints in multiple myeloma trial
Sep 29, 2023 11:24am
NICE signs off on AbbVie, J&J's Imbruvica-Venclyxta combo in CLL
Apr 21, 2023 11:30am
AbbVie cancer survey reveals CLL emotional roller coaster
Aug 24, 2022 7:35am
J&J gets EMA backing for Imbruvica-venetoclax combination
Jun 28, 2022 10:05am